SAGITTA

SAGITTA

SAGITTA contains imatinib mesylate, a second generation tyrosine kinase inhibitor, as hard capsules, is available in the following dosage forms: - 100mg capsules, packs of 60 - 400mg capsules, packs of 30

SAGITTA is indicated for the treatment of Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), Philadelphia chromosome positive acute lymphoblasti

Zahrt Aleklil is a leading company in the field of medical services, with a long history of investments in the field of sale, distribution, and provisions of all requirements of the highest standards.

Contacts

Hay Al Andalus, near the 7th of October Market, Tripoli, Libya

+218-92-234-8192

+218-91-799-0470